Funding Opportunities

The ADDF provides funding to academic centers and biotechs from around the world that are advancing therapeutic and biomarker development for Alzheimer's and related dementias. Learn more about our venture philanthropy funding model and areas of focus.

THERAPEUTICS FUNDING PROGRAMS

NOW ACCEPTING APPLICATIONS
Must be received by 5:00 pm ET on the deadline date.

Drug Development RFP
Neuroimaging and CSF Biomarker RFP
*For funding related to peripheral or digital biomarkers, see here.
Prevention RFP

ADDF/NIH Funding and SBIR/STTR Bridge Funding Opportunities

DIAGNOSTICS ACCELERATOR PROGRAMS

Learn more about the Diagnostics Accelerator here.
For funding related to neuroimaging and CSF biomarkers, see here.

ACCEPTING APPLICATIONS ON A ROLLING BASIS

Peripheral Biomarkers RFP
Digital Biomarkers RFP

OTHER FUNDING OPPORTUNITIES WITH OUR PARTNERS

Accelerating Drug Discovery for FTD RFP

Letter of Intent
Closed for 2024. TBD 2025.

Invited Full Proposal
Closed for 2024. TBD 2025.

ADDF-Harrington Scholar Program RFP 
Award decisions are anticipated by March 2025.

Letter of Intent
Closed for 2024. TBD 2025.

Full Proposal
Closed for 2024. TBD 2025.

Treat FTD Fund: Clinical trials for FTD

Letter of Intent
Closed. TBD 2025.

Invited Full Proposal
December 9th, 2024

CONFERENCE FUNDING

Supports scientific conferences that are relevant to our mission with grants up to $10,000. For more information, email grants@alzdiscovery.org with a brief summary of your conference.

ADDF FUNDING PORTAL

 

OUR FUNDING MODEL AND FOCUS AREAS

NOTE: The ADDF's venture philanthropy model means we make investments, not grants, and use all returns from those investments to support our charitable mission. Our terms are comparable with those of other venture investors. When we are working with academic institutions, in exchange for our investment we typically ask for a share of any commercial returns that may arise from the funded research. When working with biotechnology companies, we typically purchase Convertible Notes or equity, though we are also open to structuring royalty and milestone agreements with biotechs.

We have dedicated our funding to several key areas:

• IND-enabling studies and early-stage clinical trials for novel and repurposed drugs
• Development and validation of plasma, CSF, neuroimaging and digital biomarkers
• Clinical trials, comparative effectiveness research, and epidemiological studies that test whether the use or choice of drugs alters the risk for dementia or cognitive decline

Applications are reviewed throughout the year. Check back regularly for additional joint funding opportunities with our partners in non-profits, government, and industry.

Stay updated on upcoming deadlines and RFP announcements
Sign up to receive news by email.